More Studies Support Avandia Risks

Two studies published recently in the Journal of the American Medical Association seem to confirm increased dangers of the once popular diabetes drug Avandia versus those of its competitors. The authors of one study reiterated calls that Avandia should be pulled from the market. Researchers from a second study found Avandia competitor Actos to pose fewer risks of heart problems. A Food and Drug Administration panel in June voted unanimously to keep Avandia on the market.  Gardiner Harris, The New York Times  09/12/2007